BioSig Technologies, Inc. Announces $17.5 Million Common Stock Only Registered Direct Offering June 24, 2020
ViralClear Opens Enrollment with First Patient Dosing in Phase II Human Trial of Anti-Viral MMPD Oral Solution for Treatment of COVID-19 June 17, 2020
Reminder - BioSig Subsidiary, ViralClear to Host Conference Call on June 9th to Discuss Upcoming and Recent Developments for Phase II Human Clinical Trials of its Broad-Spectrum Oral Anti-Viral Candidate for Treatment of COVID-19 June 8, 2020
ViralClear adds St. David's HealthCare in Austin, Texas, to its Planned Phase II trial for its Broad-Spectrum Oral Anti-Viral Candidate for COVID-19 June 5, 2020
BioSig Technologies’s PURE EP System to be Presented in Heart Rhythm Society 2020 Science Sessions June 4, 2020
ViralClear to Host Conference Call on June 9th to Discuss Upcoming and Recent Developments for Phase II Human Clinical Trials of its Broad-Spectrum Oral Anti-viral Candidate for Treatment of COVID-19 June 1, 2020
Michael R. Dougherty Joins the Board of ViralClear Pharmaceuticals, a majority-owned subsidiary of BioSig Technologies, Inc. May 28, 2020
